Literature DB >> 12754187

Angiotensin II and the fibroproliferative response to acute lung injury.

Richard P Marshall1, Peter Gohlke, Rachel C Chambers, David C Howell, Steve E Bottoms, Thomas Unger, Robin J McAnulty, Geoffrey J Laurent.   

Abstract

Angiotensin II (ANG II), generated by activation of local renin-angiotensin systems, is believed to play an important role in tissue repair and remodeling, in part via transforming growth factor-beta (TGF-beta). Angiotensin-converting enzyme (ACE) inhibitors have been shown to abrogate experimental lung injury via a number of potential mechanisms; however, the potentially fibroproliferative role for ANG II in the lung has not been characterized. We hypothesized that, after lung injury, ANG II would stimulate fibroblast procollagen synthesis and promote lung collagen deposition in rats. In vitro, ANG II was a potent inducer of procollagen production in human lung fibroblasts via activation of the type 1 receptor and, at least in part, via the autocrine action of TGF-beta. After bleomycin-induced lung injury, an increase in lung ANG II concentration was observed by day 3 that preceded increases in lung collagen and was maintained until death at day 21. Administration of an ACE inhibitor (ramipril) reduced ACE activity, ANG II concentration, TGF-beta expression, and collagen deposition. Losartan (an ANG II type 1 receptor antagonist) also attenuated the increase in TGF-beta expression and lung collagen deposition. These observations suggest that ANG II, possibly generated locally within the lung, may play an important role in the fibrotic response to acute lung injury, at least in part via the action of TGF-beta. ACE inhibitors and receptor antagonists, already widely used clinically, should be assessed as potential new therapies for fibrotic lung disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754187     DOI: 10.1152/ajplung.00313.2002

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  103 in total

1.  Angiotensin-converting enzyme insertion/deletion polymorphism is associated with severe hypoxemia in pediatric ARDS.

Authors:  Pablo Cruces; Franco Díaz; Alonso Puga; Benjamín Erranz; Alejandro Donoso; Cristóbal Carvajal; Jan Wilhelm; Gabriela M Repetto
Journal:  Intensive Care Med       Date:  2011-10-18       Impact factor: 17.440

2.  Role of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in airway reactivity and inflammation in an allergic mouse model of asthma.

Authors:  Mehaben Patel; Mangesh Kurade; Sahith Rajalingam; Riya Bhavsar; S Jamal Mustafa; Dovenia S Ponnoth
Journal:  Immunopharmacol Immunotoxicol       Date:  2019-05-07       Impact factor: 2.730

Review 3.  Targeting tissue angiotensin-converting enzyme for imaging cardiopulmonary fibrosis.

Authors:  Omer Aras; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2008-03       Impact factor: 2.931

4.  Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.

Authors:  Gerry T M Wagenaar; Rozemarijn M A Sengers; El Houari Laghmani; Xueyu Chen; Melissa P H A Lindeboom; Anton J M Roks; Gert Folkerts; Frans J Walther
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

Review 5.  Emerging therapies for the prevention of acute respiratory distress syndrome.

Authors:  Carl A Ruthman; Emir Festic
Journal:  Ther Adv Respir Dis       Date:  2015-05-22       Impact factor: 4.031

6.  Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study.

Authors:  Whitney D Gannon; Michaela R Anderson; Anna J Podolanczuk; Steven M Kawut; Erin D Michos; Vincent Cottin; Michael Kreuter; Ganesh Raghu; R Graham Barr; David J Lederer
Journal:  Ann Am Thorac Soc       Date:  2019-11

7.  Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction.

Authors:  Arul Veerappan; Alicia C Reid; Racha Estephan; Nathan O'Connor; Maria Thadani-Mulero; Mariselis Salazar-Rodriguez; Roberto Levi; Randi B Silver
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-17       Impact factor: 11.205

8.  JunD and HIF-1alpha mediate transcriptional activation of angiotensinogen by TGF-beta1 in human lung fibroblasts.

Authors:  Amal Abdul-Hafez; Ruijie Shu; Bruce D Uhal
Journal:  FASEB J       Date:  2009-02-11       Impact factor: 5.191

9.  Hepatocyte growth factor inhibits apoptosis by the profibrotic factor angiotensin II via extracellular signal-regulated kinase 1/2 in endothelial cells and tissue explants.

Authors:  Young H Lee; Ana P Marquez; Ognoon Mungunsukh; Regina M Day
Journal:  Mol Biol Cell       Date:  2010-10-06       Impact factor: 4.138

10.  Angiotensinogen promoter polymorphisms predict low diffusing capacity in U.S. and Spanish IPF cohorts.

Authors:  My-Trang T Dang; Chenyang Gu; Jeannie I Klavanian; Katherine A Jernigan; Karen H Friderici; Yuehua Cui; Maria Molina-Molina; Julio Ancochea; Antoni Xaubet; Bruce D Uhal
Journal:  Lung       Date:  2013-05-30       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.